A research study on the true efficacy of roflumilast in COPD compared to placebo
Submission: 04 October 2025 | Acceptance: 02 November 2025 | Publication: 02 December 2025
1Qaisar Mumtaz, 2Khizer Javed Butt, 3Kazim Rodi Raja, 4Tahmoor Ghori, 5Kamran Safdar, 6Dr. Afshan Abbas
1Services Hospital Lahore
2PIMS Hospital Islamabad
3UHS Lahore
4Ganga Ram Hospital Lahore
5Mayo Hospital Lahore
6Pharmacology department. Sir Syed College of Medical Sciences for girls.
Abstract
Aim: To compare the effectiveness of roflumilast with placebo in patients with moderateto-severe chronic obstructive pulmonary disease (COPD).
Objective: The primary purpose was to evaluate lung function improvement, exacerbation frequency, and hospitalization rates from baseline (day 0) in patients receiving roflumilast versus placebo. Secondary outcomes included assessing the quality of life and the safety profile of roflumilast treatment.
Materials and Methodology: Randomized controlled trial in Outpatient department of Allied Hospital I, Faisalabad. 550 participants meeting the inclusion criteria, including age, GOLD stage 2–3 COPD, and the absence of significant comorbid respiratory diseases. Participants were randomized to receive either roflumilast or placebo for 12 months. Lung function was assessed using spirometry, while exacerbations and hospitalizations were meticulously recorded through patient diaries and medical records. Quality-adjusted life years (QALYs) were evaluated using patientcentered outcome questionnaires. Adverse events were graded for severity and systematically documented. Results: Roflumilast significantly improved lung function, demonstrating a 120 mL increase in FEV1 compared to placebo (P < 0.001). The roflumilast group experienced 28% fewer exacerbations than the placebo group (rate ratio: 0.72, P < 0.001) and a lower hospitalization rate. However, adverse events were more frequent in the roflumilast group, primarily gastrointestinal symptoms and weight loss, leading to a higher discontinuation rate (10% vs. 5% for placebo).
Conclusion: Roflumilast is an effective treatment for improving lung function and reducing exacerbation frequency and hospital admissions in patients with moderate-to-severe COPD. Although adverse effects were generally manageable, physicians should consider patient tolerability and individual risk profiles when prescribing. These findings support roflumilast as a valuable therapeutic option in COPD management, potentially enhancing clinical outcomes and quality of life.
Keywords: COPD, Roflumilast, Lung Function, Quality of Life, Exacerbations.